HIV is a global pandemic. However, anti-retroviral therapy has transformed the prognosis and, providing compliance is good, a normal life expectancy can be anticipated. This has led to increasing numbers of people with chronic prevalent, treated infection living to older ages. Musculoskeletal pain is commonly reported by HIV patients and, with resumption of near-normal immune function, HIV-infected patients develop inflammatory rheumatic diseases that require assessment and management in rheumatology clinics. Moreover, it is becoming apparent that avascular necrosis and osteoporosis are common comorbidities of HIV. This review will contextualize the prevalence of musculoskeletal symptoms in HIV, informed by data from a UK-based clinic, and will discuss the management of active inflammatory rheumatic diseases among HIV-infected patients taking anti-retroviral therapy, highlighting known drug interactions.
Background
There are 37 million people worldwide living with HIV, 2.1 million in Europe [1] . Anti-retroviral therapy (ART) has markedly reduced mortality, and can normalize life expectancy, provided diagnosis of HIV is made early [2] . Before ART, pain was a common symptom of end-stage HIV, but there is growing evidence that musculoskeletal pains (arthralgia and myalgia) remain common [3] .
Presentation of HIV de novo to rheumatologists
Anonymized blood sampling suggests that around 17% of people living with HIV are undiagnosed. Late diagnosis of HIV is associated with a 10-fold increase in mortality in the first year after diagnosis; in 2014, 613 people in the UK died, and most of these were diagnosed late [4] . Influenced by the controversy that surrounded HIV in the 1980s, some healthcare professionals are reluctant to test for HIV. Routine or 'opportunistic' offers of HIV tests by healthcare professionals (outside of sexual health services) are acceptable and facilitate greater uptake of testing [5] . HIV testing is mandated in the presence of HIV indicator conditions (Table 1 ) [6] . The authors have modified the British HIV Association guidelines to suggest some rheumatological presentations that might also lead to consideration of testing.
Does HIV cause its own musculoskeletal symptoms?
Seroconversion with HIV is often undiagnosed, but symptomatic seroconverting patients present with acute fever, lymphadenopathy, pharyngitis and rash that can be accompanied by arthralgia, myalgia and sometimes a symmetrical viral polyarthritis. In addition to this, four HIV-specific syndromes are worthy of mention: HIV arthritis, painful articular syndrome, diffuse-infiltrative lymphocytosis syndrome (DILS) and immune reconstitution inflammatory syndrome (IRIS).
HIV arthritis
It is currently unknown whether HIV causes its own primary arthritis. Other members of the same lentivirus family (visnamaedi virus and caprine arthritis encephalitis virus) are associated with arthritis in sheep and goats, respectively, and in humans, HTLV-1 is associated with arthritis. There is some experimental evidence to suggest that HIV has a direct inflammatory effect on synovial tissue in that the core viral HIV protein, p24 antigen, as well as HIV DNA and tubo-reticular inclusions have been detected in the synovial fluid of inflamed joints [7] . Worldwide studies indicate an increased prevalence of asymmetric seronegative arthritis with or without axial involvement and with or without skin psoriasis occurring among people living with HIV often, but not always, naïve to ART [817] . Reproduced from [6] , with kind permission of British HIV Association, with the addition of suggested rheumatological indicator conditions. HIV antibody testing (and Hepatitis B and C) is also recommended for rheumatological patients prior to commencement of biologic therapies.
www.rheumatology.oxfordjournals.org This was particularly noteworthy in Africans among whom seronegative arthritis was uncommon prior to the HIV epidemic. In contrast, a large US casecontrol study that investigated the rates of reactive arthritis and tested for HIV found no excess of reactive arthritis [9] and in another US study, including 1100 HIV-positive patients, only a slight excess of PsA was found and no increased risk of rheumatoid or other inflammatory arthritis [18] . According to one description, HIV arthritis is an acute large joint arthritis, lasting <6 weeks, in the absence of HLA B27 positivity or radiological changes, distinct from any other recognized rheumatological condition, not triggered by detectable infections and with no other clinical features recognizable as another inflammatory arthropathy [19] . Others have described it as a self-limiting, asymmetric oligoarthritis, a symmetrical polyarthritis, or a monoarthritis [20] . With such broad case definitions, it is currently unclear whether HIV arthritis is a distinct clinical entity.
Painful articular syndrome
The term painful articular syndrome was first used by Berman et al.
[13], describing acute arthralgia presenting typically in one (usually large) joint in HIV-positive patients. The pain was of such severe intensity that patients attended emergency services and needed therapy with anti-inflammatories or opiates to relieve the pain, but it was not associated with synovitis and was ultimately short-lived (224 h). They reported a prevalence of 10% among US patients in the late stages of HIV as well as another cohort of Argentinian patients [14] . A number of other case series did not report any cases of painful articular syndrome [12, 2123] but it has been described in an Indian cohort study, with a prevalence of 3.3% [24] among ART-treated patients. With such variation in the literature, it is possible that painful articular syndrome is a feature of HIV contracted through intravenous drug use or is peculiar to some countries or populations of patients, but further research is required.
DILS
DILS is similar to SS but is associated with HIV. DILS often causes salivary gland swelling and chronic sicca symptoms, and is frequently associated with hypergammaglobulinaemia. The commonest presentation (88100%) is with bilateral parotid gland enlargement [25, 26] , but sicca symptoms can occur without gland swelling. As is seen in Sjogren's, extra-glandular manifestations may occur, including lymphocytic infiltrative pneumonitis (3159%), myositis (26%), hepatitis (423%), neuropathology (24%), nephropathy, neuropathy (23.5%) and panuveitis [27] . Lymphoid infiltration may cause swelling in the liver, spleen and lymph nodes [2528] . Pseudo-tumours have also been described in non-lymphoid tissue including the CNS, skin and digestive tract [28] . Sensory neuropathy, mononeuritis multiplex, radiculopathy, facial nerve palsy and lymphocytic meningitis have all been reported [29] as has neoplastic conversion to nonHodgkin's lymphoma [25] .
The diagnosis [28] relies upon histological confirmation of salivary or lacrimal lymphocytic infiltration, after exclusion of granulomatous or neoplastic causes. DILS patients should be anti-Ro/SSA and anti-La/SSB negative, with CD8 + rather than CD4 + glandular tissue infiltration. It is this that is the key diagnostic feature of DILS in the presence of high titres of circulating CD8 + lymphocytes. DILS was reported commonly in the pre-ART era (particularly in Afro-American and Black African patients), when it was generally a good prognostic sign for the HIV infection [26, 30] . For example, 33.7% of people with HIV referred to one Rheumatology service between 1994 and 1997 had DILS, but this prevalence dropped to 7.5% over the subsequent 6 years during which ART became available [25] . Cases of DILS have been reported in which the CD4 + count was not markedly diminished [29] . ART improved the DILS symptoms in most patients, although DILS may persist or relapse despite effective ART. Treatment with adjunctive glucocorticoids has been required in a small number of cases [31] . The clinical presentation may have been modified since ART availability and it is probably under-diagnosed [31] .
IRIS
IRIS describes a group of inflammatory disorders associated with a paradoxical worsening of pre-existing infectious or autoimmune conditions after commencement of ART. Rheumatological and non-rheumatological conditions have been reported, including sarcoidosis, RA [3233], DLE and SLE, myositis, Grave's disease, Hashimoto's thyroiditis, multiple sclerosis and adult-onset Still's disease [34] . On average, IRIS occurs 9 months after commencement of ART but symptoms may occur within days.
Osteoporosis
Data from studies of people living with HIV compared with controls consistently show a higher rate of low bone mass in HIV [35] . In a meta-analysis of these studies, a prevalence of 616% of osteoporosis and 3365% of osteopenia was estimated and protease inhibitors were reported to cause increased risk [36] . Subsequently, however, another research group meta-analysed these studies and showed that adjustment for BMI considerably attenuated the bone effects [37] . Longitudinal data show that initiation of any ART regimen is associated with a 12% reduction in bone mass over 12 months with subsequent stabilization. The effects of ART on bone have been ascribed to uncoupling of the bone turnover cycle with excess bone resorption after 3 months unmatched by bone formation for 12 months. Tenofovir disoproxil fumarate therapy is associated with proximal renal tubular dysfunction and, rarely, Fanconi syndrome [38] . Even without causing overt phosphate deficiency, it appears to cause more bone loss over the first 12 months of ART than some other drugs (particularly if given with a boosting agent such as ritonavir or cobicistat) and has been shown to cause bone loss not only on initiation of therapy in naïve patients but also on switching to therapy [39] . Even without effects of ART, an increased risk of osteoporosis could be predicted given that people living with HIV are prone to comorbidities associated with low bone mass (hypogonadism, renal disease, liver disease, diabetes mellitus, low BMI, malabsorption, etc.). Moreover, there are immunological effects of the virus itself on osteoblast and osteoclast function and there are recognized effects of the associated high levels of circulating pro-inflammatory cytokines (TNFa, IL-1, IL-6). There is now increasing evidence that people living with HIV sustain more low-trauma fractures than controls [40] . HIV may grow to be an important risk factor for low-trauma fractures at older ages. In particular, there must be concern about the impact of vertically infected patients on their attainment of peak bone mass and for HIV positive postmenopausal women.
Avascular necrosis
Avascular necrosis (AVN) was first reported in people living with HIV in 1990 and it was speculated by the authors that its incidence was increased compared with that seen in the background population [41] . Keruly et al. [42] reported a 1% annual incidence of symptomatic osteonecrosis in HIV-positive patients, a rate that again was higher than that reported in general population studies. Additionally, Miller et al. [41] scanned 339 people living with HIV and found evidence of asymptomatic osteonecrosis in 4.4%, a rate considerably greater than that expected. Although these studies suggest a higher rate of occurrence of AVN, it is as yet unclear whether this reflects a true increased risk or increased rates of detection because HIV patients are under much closer surveillance. Moreover, it is unknown whether it is infection with HIV that causes increased risk or if, in fact, these patients have an increased number of the risk factors for AVN in the general population (alcohol excess, glucocorticoids, hypogonadism). Some, but not all, studies have implicated ART as an independent risk factor [43] . A recent surgical study suggested that people living with HIV presented younger than non-HIV patients, were more likely to be affected bilaterally and presented only a mean of 25 months post symptom onset as compared with 4 years [44] . The principal risk factors are the same as those found in the general population, namely male gender, glucocorticoid use, excess alcohol and hypogonadism. Having observed that a significant number of patients with HIV had required total hip replacement (despite the median age of the cohort being 42 years), we undertook a casecontrol study, comparing the past exposures of the cases with a total hip replacement with five controls matched for age, gender and ethnicity [45] . Overwhelmingly the single most important risk factor for hip replacement, performed at a median age of 47 years, was exposure to systemic glucocorticoids (odds ratio (OR) = 44.6, P < 0.0001), which had occurred in many cases at the time of their presentation with newly diagnosed HIV and pneumocystis pneumonia.
Inflammatory arthritis and HIV
Inflammatory arthritis coexistent with HIV has been described in a considerable number of case series. The reader should, however, bear in mind that these studies come from across the globe and therefore that diagnostic classification systems have been applied with some variation, depending upon whether rheumatological expertise and indeed tests were available.
RA
Prior to ART, case reports described patients diagnosed with RA who improved clinically or went into remission after becoming infected with HIV [4648] . It was thought that depletion of CD4 + helper/induced lymphocytes by the virus reduced the autoimmune activation that was needed to sustain inflammatory joint disease. It became received wisdom that HIV and RA could not co-exist. As a result, even when patients presented with symmetrical polyarthritis and radiographic erosive changes persisting beyond 6 months, it was still not classified as RA [13] . In some case series, patients with a symmetrical erosive arthropathy were classified with RA, but in others such a presentation was attributed to a more destructive and symmetrical type of HIV arthritis. In one study, the radiological features of four patients were described as 'rheumatoid-like' [49] but the patients were diagnosed with symmetrical polyarthritis. Stein described the clinical presentation of 58 patients with HIV and arthritis, suggesting that eight of these had a rheumatoid-like pattern, but reported that only one developed erosive changes [50] . It is clear since then that RA and HIV are not mutually exclusive [13, 21, 24, 51, 52] . Across studies, estimated rates of prevalence range between 0.1 and 5% [16, 23, 24, 32, 50] . A predominance of RA has been reported among men living with HIV but this likely reflects the gender balance of prevalent HIV. The average age at diagnosis of RA in the literature falls between 27 and 58 years [50] with a range of duration of ART between 8 months and 9 years [33, 53] . One group reported that 50% of their RA cases were associated with cigarette smoking. In general, RA appears to develop when the HIV is reasonably well controlled, that is, with CD4 + counts >200 cells/mm 3 , and/or when viral activity is undetectable [24, 52, 53] . Tarr and colleagues [54] reported on 85 adult patients in South Africa recognized to have both conditions, 43 of whom contracted HIV after their RA had been diagnosed. Among these, they showed significant improvement in all measurements of disease activity (including swollen and tender joint counts, CRP, DAS-28), with the exception of ESR, after seroconversion to HIV. These improvements were, however, matched by a control group of RA patients who did not develop HIV and were not significantly different except that the HIV group had a better mean patient global assessment score and a higher mean ESR. Improved disease activity measures were maintained in the HIV group despite withdrawal of MTX on HIV www.rheumatology.oxfordjournals.org diagnosis in the majority of cases (all except five). Their study highlighted difficulties in monitoring patients with inflammatory arthritis, who happen to be HIV positive. A persistently elevated ESR is a feature of living with HIV [17] , and they demonstrated that the 28 joint count DAS28 using ESR over-estimated disease activity by as much as 30% when compared with DAS28 CRP.
Low-titre autoantibodies, such as RF [10, 55] , ACPA antibodies [56] and ANA, can occur in the context of untreated HIV. Since ART, the prevalence of RF appears to have reduced [11] with rates comparable to those found in general population studies [24, 50] . Rates of ACPA positivity as high as 15% have been reported in HIV-positive patients naïve to ART (mostly at low titre) and rates reportedly dropped to <6% after 6 months of ART [55] . In the same study, antibodies to RF were positive in 47% of patients (again at low titre) but all the antibody titres reduced after 6 months of ART with no patient developing RA after 1 year follow-up [55] .
PsA
Psoriasis has long been recognized as a manifestation of HIV. Psoriasiform rash with arthritis was reported in several cohort studies pre-and post-ART [13, 15, 22, 5759]. The prevalence rate of PsA in HIV has been estimated between 0.02% [23] and 5.7% [15] . Comparing these estimates with the estimated population prevalence 0.25% of PsA in the USA, it might be concluded that HIV increases the risk of PsA. However, two large US studies [9, 18] reported no cases of PsA among more than 2000 HIV-infected men, although another hypothesis is that the absence of PsA could be explained by the fact that most of the HIV patients in these studies were in the early (asymptomatic) stages of the infection. In one longitudinal study over 11 years [17] , there were three incident cases of PsA among 395 HIV-positive individuals (estimated incidence rate 0.07% per annum), a rate that approximates to the 0.05% incidence rate in general population studies.
The pre-ART studies also suggested that HIV patients had more severe and persistent skin psoriasis and more severe and deforming PsA that was less likely to respond to therapy. Another interpretation, however, is that the severity of the psoriasis and PsA reflected instead the fact that most of the patients had advanced HIV (WHO stages 3 and 4) [8, 13, 58] .
In Africa, PsA was uncommon pre-HIV, remains uncommon in HIV-negative individuals, but has been diagnosed increasingly since the HIV pandemic among positive patients [23] . A study in Zimbabwe involving 64 people living with HIV and rheumatological symptoms found three patients with severe, persistent PsA [50] . In a prospective Zambian study of 702 people with inflammatory arthritis, 28 patients were diagnosed with PsA over 44 months amongst whom 27/28 (92%) had HIV, mostly in the early stages [59] . PsA was the presenting feature in each of these patients. The skin involvement was described as symmetrical and extensive occurring simultaneously with polyarthritis that was seronegative, asymmetrical and erosive often involving the lower limbs. Among the seven PsA patients who developed AIDS, active skin lesions continued throughout but the arthritis tended to remit towards the pre-terminal stage of disease. Lower rates of PsA have been reported in other studies in Africa [23] and Asia pre-and post-ART [21, 22, 60] .
When zidovudine (azidothymidine) became the first available antiretroviral drug, it was reported to improve skin psoriasis associated with infection [58] . It is, however, less clear whether ART has impacted on PsA. According to a Spanish study, the three patients who developed PsA during a 7-year study were all naïve to ART [61] . It is possible that PsA is a feature of end-stage HIV infection seen more prior to ART but there is currently insufficient information in the post-ART era.
AS
Although AS is the most common seronegative spondyloarthropathy in the Western world, it appears to have been rarely described as co-existent with HIV before ART became available. AS has been reported recently in studies in France [52] and Burkina Faso [23] . In Africa, where there is very low prevalence of HLA B27, cases of AS are rare with and without HIV infection. It has been postulated that the immunological mechanisms that underlie AS are independent of CD4 + T cells and therefore would not be affected by HIV [62] . In a Zambian study, 14 patients presented with spontaneous sacro-iliitis, elevated ESR and positive sacro-iliac stress tests, with normal radiographs [63] . Four of these 14 went on to develop polyarthritis and enthesitis at follow-up and therefore were classified with undifferentiated spondyloarthropathies. Longer term follow-up would be needed to determine whether these patients developed radiographic features of AS. In most studies, undifferentiated spondyloarthropathy appears common and it may be that a proportion of AS is being classified as undifferentiated spondyloarthropathy in the absence of radiographic studies, HLA B27 testing or long enough duration of follow-up.
Reactive arthritis
The estimated rates of occurrence of reactive arthritis in people living with HIV pre-ART vary widely from 0 to 11%, most likely because of the classification issues described earlier. . This may reflect a true difference in susceptibility to reactive arthritis between North Americans and Central and South Americans. However, it more likely reflects differing rates of risktaking behaviour that determine the way in which HIV is acquired. A wide range of infectious triggers can lead to reactive arthritis but a common association is with sexually transmitted infections. High-risk behaviours that increase the risk of sexually acquired HIV also increase the risk of the range of sexually transmitted infections. Interestingly, in countries where the principle mode of acquisition of the virus is intravenous drug use, such as Spain, lower rates of reactive arthritis have been reported [10, 61] and the commonest musculoskeletal manifestations are instead pain and infections [16, 64] .
Studies from African countries suggest increasing rates of reactive arthritis since 1989 with a rise in prevalence strongly associated with HIV. Among a sample of 65 Zambian patients diagnosed with reactive arthritis, 61 (95%) were HIV positive [65] and 37.5% of a group of Zimbabwean HIV-infected patients developed reactive arthritis [50] . Lower rates of occurrence have been reported in other African countries; for example, in Congo seven patients were classified with reactive arthritis over 1 year among whom two (29%) were HIV positive [60] . This apparent variability may, however, be explained instead through classification. During the Congo study, 32 patients were instead labelled with HIV arthritis. No cases of reactive arthritis were reported in series from China [21] or Thailand [22] .
It is possible that reactive arthritis occurs as a latestage manifestation of HIV, which would explain the apparent low rates of occurrence in early HIV [9, 18]. Certainly, there have been fewer publications about reactive arthritis since ART in the developed world. However, it could be that high-risk sexual practices have been modified in the HIV era so that there is less transmission of arthritogenic urogenital and enteric infections [9] . Another possible explanation is that effective ART impacts the development and course of reactive arthritis. This last hypothesis was not borne out by a study comparing rates of reactive arthritis among 80 HIV patients, 38 taking ART and 42 ART-naïve among whom there was no difference in rates of reactive arthritis [66] .
CTD
Numerous case reports and small clinical series document the co-existence of HIV with SLE and CTDs such as SS, sarcoidosis and Behc¸et's disease [13, 6769] . For example, more than 400 cases of co-existent SLE and HIV have been described in the literature [70, 71] . A detailed discussion of these conditions is outside the scope of the present review.
Inflammatory rheumatic disorders in a UK cohort in the post-ART era
Between January 2005 and December 2012, 363 HIVpositive patients with musculoskeletal symptoms were referred to one consultant rheumatologist out of a cohort of 2042 prevalent HIV-infected patients [1837 (90%) male]. The majority (310, 85%) of patients referred had no evidence of an inflammatory rheumatic disease but instead were diagnosed with regional musculoskeletal pain, specific soft tissue disorders, chronic widespread pain or OA. Analysis of the clinical features and assigned diagnoses among the remaining 53 is presented in Table 2 . Most inflammatory diagnoses were not made more often than would be expected for the general population, with the possible exception of seronegative arthritides, as has been reported in other case series. However, a referral bias cannot be ruled out in this specialized clinic.
Treatment of inflammatory rheumatic disease in the context of HIV
Treatment of inflammatory rheumatic disease in the context of HIV is challenging. Patients treated with disease modifying drugs in the pre-ART era generally had poor outcomes [8, 58] . However, among patients taking ART reliably and with complete suppression of viral activity, use of disease-modifying anti-rheumatic therapies appears safe and well-tolerated, particularly if the CD4 + count is above 200 cells/mm 3 . Before commencing any new drug in a patient taking ART, clinicians are recommended to check for potential interactions using the University of Liverpool HIV drug interactions website (http://www.hiv-druginteractions.org/). Table 3 reviews the published use of DMARDs and biological therapies among patients with recognized prevalent HIV.
Glucocorticoids HIV-infected patients have been widely treated with glucocorticoids across the whole range of inflammatory conditions. As expected, the toxicities that occur in the general population also occur in HIV patients. Importantly, however, one of the most widely used protease inhibitors, ritonavir, inhibits steroid metabolism through potent inhibition of CYP3A4 and CYP2D6 [95] (the same effect is seen with the more recently licensed boosting agent cobicistat). The effect of these drugs, therefore, is to enhance glucocorticoid activity by up to 50%, and doses therefore need to be adjusted accordingly. Importantly, people living with HIV also have elevated risk of AVN, osteoporosis and fractures so that appropriate bone protection should be carefully considered, particularly in those taking ritonavir.
Intra-articular glucocorticoids
It has been recognized for some time that concomitant use of ritonavir with the potent inhaled corticosteroid fluticasone is associated with severe side effects including Cushing's syndrome. Similarly, a small number of cases have been reported in which patients treated with a single intra-articular injection of triamcinolone developed steroid-induced crises, including multi-focal osteonecrosis and Cushing's syndrome [9698] . As mentioned above, ritonavir and cobicistat inhibit the metabolism of steroids through the cytochrome P450 pathway. It is therefore recommended that intra-articular triamcinolone is not administered to patients taking either of these drugs. It appears that methylprednisolone may be administered more safely but dosage adjustment is required.
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TABLE 2
Inflammatory rheumatic diseases diagnosed in 53 patients assessed in UK HIV rheumatology clinic .8 All four patients had psoriasis at presentation. One patient (25%) was HLA B27 positive. One patient (25%) had severe plaque psoriasis and dactylitis. Two patients (50%) displayed active skin psoriasis and psoriatic nail dystrophy. These three patients (75%) were treated with MTX and anti-inflammatories. One patient had a significant past history of skin psoriasis (although no active disease at presentation) and despite radiographic confirmation of PsA, this patient chose not to receive pharmacological treatment Review reported published use in 27 patients [91] . Largest series was eight patients [89] , all with CD4 + cell count >200 cells/mm 3 and viral load <60 000 copies/ml. No patients experienced HIV progression or opportunistic infections over 48 months followup. In one case report, the patient experienced frequent secondary infections that required discontinuation after 4 months (CD4 <50) [88] . There are few long-term data published presently but one patient, co-infected with HIV and hepatitis C was successfully treated with infliximab over 11 years of follow-up without serious infection [90] Infectious complications seen in 4/27 (15%) patients. Particular caution over screening for TB in patients with HIV considered for anti-TNF? therapy. Used safely in three patients Rituximab Widely used as part of lymphoma treatment. Two studies of rituximab monotherapy in HIV-associated multicentric Castleman disease showed no increased risk of infection but a potential for reactivation of Kaposi sarcoma [92, 93] . HIV viral load and absolute CD4 counts were not affected during therapy [93] . Successful and safe use to induce pemphigus remission [94] No recognized drug interactions. 
Conclusion
Rheumatologists will encounter growing numbers of people living with HIV as they live longer with the infection controlled by ART. Musculoskeletal symptoms are common, much of which are explained as myalgia, arthralgia and soft tissue rheumatism. However, a small proportion of patients will be diagnosed with inflammatory rheumatic diseases requiring careful balance of diseasemodifying anti-rheumatic drugs and biologics with ART. Although there is still limited published evidence, it appears that rheumatological therapies can be prescribed safely providing that viral activity is completely suppressed and CD4 + counts are above 200 cells/mm 3 .
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